Pharmafile Logo
Pharmafocus logo
Advanced Search

Humira

Showing 15 posts of 90 posts found.

humira_abbott__4

AbbVie and Mylan reach US marketing agreement for Humira biosimilar

July 18, 2018
Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma

AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

News
abbvieuse_054_low

AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

April 11, 2018
Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …

News
humira_abbott__4

Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

April 6, 2018
Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News
bi_german_building_at_night

Boehringer celebrates EU approval of Humira biosimilar

November 14, 2017
Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar

Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …

News
humira_abbott_

Five more biosimilar-free years for AbbVie’s megablockbuster

September 28, 2017
Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …

News
sandoz

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017
Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …

News
abbviehqe_011_low

AbbVie suffers knock to Humira patent

May 19, 2017
Medical Communications, Sales and Marketing AbbVie, Humira, patents

Humira is the largest selling pharmaceutical drug in the world. The treatment for rheumatoid arthritis brought in over $16 billion …

News
abbvie_0

UK High Court rules against AbbVie’s Humira patents

March 6, 2017
Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …

News
janssen_latest_logo_on_sign_closer

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

March 6, 2017
Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …

News

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …

News
ema_building_2

Amgen drug pair become first Humira biosimilars to win EU approval

January 30, 2017
Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis

Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …

News
bi_german_building_at_night

Boehringer steps into Humira race with US and EU biosimilar filings

January 19, 2017
Sales and Marketing Boehringer Ingelheim, Humira, biosimilar

Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …

News

Pfizer announce positive results for Humira biosimilar

January 6, 2017
Medical Communications, Research and Development, Sales and Marketing Humira, Pfizer, biosimilar

Pfizer has released the successful Phase 3 results to its biosimilar to AbbVie’s blockbuster Humira, meeting its primary endpoint in …

News

Latest content

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024

FDA approves Roche’s HPV self-collection screening option

May 15, 2024

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024